Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

Phase 2 Active not recruiting 42 enrolled Memorial Sloan Kettering Cancer Center Incyte Corporation · collab

NaSingle-groupOpen-labelTreatment

Summary

The researchers are doing this study to find out whether combining the study drugs palbociclib and INCMGA00012 is an effective and safe treatment for advanced liposarcoma. "Funding Source - FDA OOPD"

Timeline

Start: 2020-06-17
Primary completion: 2026-06
Completion: 2026-06

Publications

Rosenbaum E, Seier K, Gularte-Merida R, Seffar E, Dickson MA, Avutu V, Banks LB, Chan JE, Chi P, Gounder MM, Kelly CM, Keohan ML, Maki RG, Movva S, Reed D, Desir R, Biniakewitz M, Cho JM, Duchemin M, Erinjeri JP, Lefkowitz RA, Koff A, Singer S, Tap W, Qin LX, D'Angelo S. Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma. J Immunother Cancer. 2026 May 4;14(5):e014346. doi: 10.1136/jitc-2025-014346.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Palbociclib	Small molecule	125 mg	Oral
Subject	Retifanlimab	Monoclonal antibody	500 mg	Intravenous

Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

Summary

Timeline

Publications

Drugs

Indications